Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer.

Alshaebi, Fadhl; Safi, Mohammed; Algabri, Yousif A; Al-Azab, Mahmoud; Aldanakh, Abdullah; Alradhi, Mohammed; Reem, Alariqi; Zhang, Caiqing.

Afiliação

Alshaebi F; Department of Respiratory, Shandong Second Provincial General Hospital, Shandong University, Jinan, Shandong, China.
Safi M; Department of Respiratory, Shandong Second Provincial General Hospital, Shandong University, Jinan, Shandong, China.
Algabri YA; Department of Biomedical Engineering, School of Control Science and Engineering, Shandong University, Jinan, Shandong, China.
Al-Azab M; Department of Immunology, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou Medical University, Guangzhou, China.
Aldanakh A; Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Alradhi M; Department of Urology, The Affiliated Hospital of Qingdao Binhai University, Qingdao, Shandong, China.
Reem A; Faculty of Medicine and Health Sciences, Amran University, Amran, Yemen.
Zhang C; Department of Respiratory, Shandong Second Provincial General Hospital, Shandong University, Jinan, Shandong, China.

Front Oncol ; 13: 1099696, 2023.

Article em En | MEDLINE | ID: mdl-36798830

Palavras-chave

cancer therapy; cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); immune checkpoint inhibitors (ICIs); interluikin-34 (IL-34); programmed cell death protein 1 (PD-1); tumor microenvironment

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article